Immix Biopharma (IMMX) Income from Continuing Operations (2021 - 2026)
Quarterly results put Income from Continuing Operations at 10086687.0 for Q1 2026, down 122.05% from a year ago — trailing twelve months through Mar 2026 was 34982772.0 (down 4300.29% YoY), and the annual figure for FY2025 was 29438613.0, down 1759.03%.
Immix Biopharma has reported Income from Continuing Operations over the past 6 years, most recently at 10086687.0 for Q1 2026.
- Income from Continuing Operations reached 10086687.0 in Q1 2026 per IMMX's latest filing, up from 10687830.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 15302762.0 in Q4 2024 and bottomed at 10687830.0 in Q4 2025.
- Median Income from Continuing Operations over the past 5 years was 4405850.0 (2024), compared with a mean of 3819651.88.
- The largest annual shift saw Income from Continuing Operations tumbled 649.04% in 2022 before it skyrocketed 396.83% in 2024.
- Over 5 years, Income from Continuing Operations stood at 3799837.0 in 2022, then crashed by 35.67% to 5155366.0 in 2023, then surged by 396.83% to 15302762.0 in 2024, then crashed by 169.84% to 10687830.0 in 2025, then increased by 5.62% to 10086687.0 in 2026.
- Business Quant data shows Income from Continuing Operations for IMMX at 10086687.0 in Q1 2026, 10687830.0 in Q4 2025, and 7585692.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - | -10.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.09 Mn |
| Dec 31, 2025 | -10.69 Mn |
| Sep 30, 2025 | -7.59 Mn |
| Jun 30, 2025 | -6.62 Mn |
| Mar 31, 2025 | -4.54 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Sep 30, 2024 | -7.15 Mn |
| Jun 30, 2024 | -4.41 Mn |
| Mar 31, 2024 | -5.33 Mn |
| Dec 31, 2023 | -5.16 Mn |
| Sep 30, 2023 | -4.34 Mn |
| Jun 30, 2023 | -3.60 Mn |
| Mar 31, 2023 | -2.50 Mn |
| Dec 31, 2022 | -3.80 Mn |
| Sep 30, 2022 | -1.54 Mn |
| Jun 30, 2022 | -1.56 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -22.76 Mn |
| Sep 30, 2021 | -403,265.00 |
| Jun 30, 2021 | -208,638.00 |
| Mar 31, 2021 | -1.02 Mn |